Charles River Acquires Blue Stream Laboratories
PTSM: Pharmaceutical Technology Sourcing and Management
Charles River acquired Blue Stream Laboratories, an analytical contract research organization.
Charles River Laboratories announced on June 27, 2016 that it has acquired Blue Stream Laboratories, an analytical contract research organization (CRO) supporting the development of complex biologics and biosimilars. This acquisition will combine Blue Stream and Charles River’s existing discovery, safety assessment, and biologics capabilities, Charles River said in a press announcement. Blue Stream is located in Woburn, Massachusetts, and is recognized for its work in structural and function protein characterization programs, the development and validation of assays for cGMP lot release, and stability programs.
“Our continued investment in expanding our biologics portfolio, through the development of new assays and capabilities, has enabled us to provide a broader testing solution for our clients,” James C. Foster, chairman, president, and CEO of Charles River said in a statement. “This investment is particularly important now, when the number of biologic and biosimilar drugs in development is increasing. The acquisition of Blue Stream will meaningfully enhance the ability of our Biologic Testing Solutions business to compete effectively in this high-growth market segment.”
Source: Charles River Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
